Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Waters, Prosolia Exclusive Agreement for DESI Technology for Clinical MS Applications

Published: Monday, June 16, 2014
Last Updated: Tuesday, June 17, 2014
Bookmark and Share
Prosolia DESI Technology now available on SYNAPT G2 Si and Xevo G2-XS QTof mass spectrometers.

Waters Corporation has signed an agreement with Prosolia, Inc. (Indianapolis, IN) for the exclusive rights to DESI (Desorption Electrospray Ionization) technology for clinical research applications for use with Waters®  time-of-flight mass spectrometers, including its SYNAPT® G2 Si and Xevo® G2-XS QTof mass spectrometers. The announcement came at the 62nd conference of the American Society of Mass Spectrometry (ASMS).

When used for clinical research studies, DESI is a non-destructive means by which researchers using mass spectrometry can determine, with specificity and speed, the molecular distributions of drugs, lipids and metabolites from human tissue samples. Otherwise known as in vitro “tissue imaging”, it allows scientists to potentially distinguish healthy tissue from diseased tissue.

“By combining Prosolia’s DESI with Waters' time-of-flight mass spectrometers, we see the potential to advance clinical research in meaningful ways,” said Dr. Rohit Khanna, Vice President of Worldwide Marketing and Informatics for the Waters Division. “This agreement with Prosolia is an important step in fulfilling our vision of improving human health by partnering with the biomedical community to make breakthrough scientific discoveries and translate them into healthcare solutions.”

A bottleneck in life science research is the time and expertise required for sample preparation. Tissue sample preparation can be a tedious process that often involves multiple steps, delaying the time to a result, decreasing productivity and increasing the probability for error. DESI eliminates this bottleneck by enabling direct, automated analysis of tissue samples thereby reducing the requirement for extensive sample preparation and enabling high throughput sample analysis. These capabilities translate into lower laboratory operational costs, streamlined workflows and generate results faster than traditional approaches.

“Waters is a natural choice for Prosolia to partner with to advance the DESI technology in the clinical research space,” said Dr. Justin Wiseman, Chairman, President & CEO of Prosolia. “Waters’ mass spectrometry technology and vision of a healthier future for humanity appealed to us on many levels and we are looking forward to a long and successful relationship.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Waters Corporation Announces Christopher J. O'Connell as CEO
Chris joins Waters® from Medtronic plc.
Thursday, July 02, 2015
Waters Centers of Innovation Program Honors CSU Laboratory
Proteomics and metabolomics facility recognized for innovation in biological mass spectrometry.
Wednesday, October 29, 2014
Waters Q3 Revenues up 8 Percent
Company reports third quarter sales of $493 million, an increase of 8% versus sales of $457 million in the third quarter of 2013.
Tuesday, October 21, 2014
Waters, Chinese Pharmacopeia Commission Establish Joint Open Laboratory
Located in the laboratory building of Beijing Zhendong Guangming Drug Research Institute, the new facility is over 400m2.
Thursday, July 10, 2014
New Solutions to Old Challenges
Waters Corporation introduces a new NuGenesis Lab Management System (LMS) that integrates sample management functions and business operations across the enterprise. Technology Networks' Editor Helen Gillespie interviewed Waters' Garrett Mullen for details.
Tuesday, July 01, 2014
Waters, Omics LLC Partner to Advance Petroleum Sample Analysis
Collaboration Combines the Value of Ion Mobility Mass Spectrometry (IM-MS) and Accurate Mass Information with Petroleomics Data Processing.
Monday, June 16, 2014
Waters ACQUITY UPLC TQD System Receives Chinese FDA Approval
Chinese FDA approves ACQUITY UPLC TQD system for routine diagnostic applications and neonatal metabolites diseases screening.
Thursday, June 05, 2014
Waters ACQUITY QDa Detector Takes Pittcon Editors' Award
Product receives Editors' Silver award for the most innovative product introduced at Pittcon 2014.
Monday, March 10, 2014
Waters Report 8% Revenue Increase
Fourth quarter 2013 sales were $565 million, an increase of 8% compared to sales of $522 million in the fourth quarter of 2012.
Tuesday, January 28, 2014
Waters Teams With Biochemical Society on Proteomics Training Day and Symposium
The consecutive events will take place on March 24 - 27, 2014 in Chester, England.
Wednesday, November 27, 2013
Waters Acquires Nonlinear Dynamics
Nonlinear Dynamics is best known for their Progenesis software which offers researchers unique ways to analyze and visualize the raw proteomic data.
Thursday, August 08, 2013
Waters Sponsors Clinical Chemistry Fellowship
The two-year, postdoctoral fellowship at the University of California, San Diego School of Medicine will emphasize a combination of training in classical clinical chemistry and specialty areas.
Wednesday, July 31, 2013
New Phenome Centre will Decipher Roles of Nature and Nurture in Human Health
The MRC-NIHR Phenome Centre will examine around one hundred thousand blood and urine samples every year, putting the UK at the forefront of a revolution in health and medical research.
Wednesday, June 05, 2013
Waters Users’ Meeting at ASMS 2013
Register for the Waters Users’ meeting at ASMS 2013 and learn about the latest developments in Mass Spectrometry from Waters experts as we reveal our new technologies and solutions.
Monday, May 13, 2013
Waters Reports First Quarter 2013 Financial Results
Waters Corporation reported first quarter 2013 sales of $430 million, an increase of 2% from sales of $420 million in the first quarter of 2012.
Wednesday, April 24, 2013
Scientific News
Health Risks of Saturated Fats Aggravated by Immune Response
Research shows that the presence of saturated fats resulted in monocytes migrating into the tissues of vital organs.
Changing the Biological Data Visualisation World
Scientists at TGAC, alongside European partners, have created a cutting-edge, open source community for the life sciences.
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!